339 related articles for article (PubMed ID: 15718420)
1. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model.
Grundler R; Miething C; Thiede C; Peschel C; Duyster J
Blood; 2005 Jun; 105(12):4792-9. PubMed ID: 15718420
[TBL] [Abstract][Full Text] [Related]
2. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.
Choudhary C; Schwäble J; Brandts C; Tickenbrock L; Sargin B; Kindler T; Fischer T; Berdel WE; Müller-Tidow C; Serve H
Blood; 2005 Jul; 106(1):265-73. PubMed ID: 15769897
[TBL] [Abstract][Full Text] [Related]
3. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.
Kelly LM; Liu Q; Kutok JL; Williams IR; Boulton CL; Gilliland DG
Blood; 2002 Jan; 99(1):310-8. PubMed ID: 11756186
[TBL] [Abstract][Full Text] [Related]
4. The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3.
Spiekermann K; Dirschinger RJ; Schwab R; Bagrintseva K; Faber F; Buske C; Schnittger S; Kelly LM; Gilliland DG; Hiddemann W
Blood; 2003 Feb; 101(4):1494-504. PubMed ID: 12406902
[TBL] [Abstract][Full Text] [Related]
5. Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells.
Bagrintseva K; Schwab R; Kohl TM; Schnittger S; Eichenlaub S; Ellwart JW; Hiddemann W; Spiekermann K
Blood; 2004 Mar; 103(6):2266-75. PubMed ID: 14604974
[TBL] [Abstract][Full Text] [Related]
6. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
Marhäll A; Heidel F; Fischer T; Rönnstrand L
Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308
[TBL] [Abstract][Full Text] [Related]
7. Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3).
Murata K; Kumagai H; Kawashima T; Tamitsu K; Irie M; Nakajima H; Suzu S; Shibuya M; Kamihira S; Nosaka T; Asano S; Kitamura T
J Biol Chem; 2003 Aug; 278(35):32892-8. PubMed ID: 12815052
[TBL] [Abstract][Full Text] [Related]
8. FLT3-TKD mutation in childhood acute myeloid leukemia.
Liang DC; Shih LY; Hung IJ; Yang CP; Chen SH; Jaing TH; Liu HC; Wang LY; Chang WH
Leukemia; 2003 May; 17(5):883-6. PubMed ID: 12750701
[TBL] [Abstract][Full Text] [Related]
9. Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).
Kindler T; Breitenbuecher F; Kasper S; Estey E; Giles F; Feldman E; Ehninger G; Schiller G; Klimek V; Nimer SD; Gratwohl A; Choudhary CR; Mueller-Tidow C; Serve H; Gschaidmeier H; Cohen PS; Huber C; Fischer T
Blood; 2005 Jan; 105(1):335-40. PubMed ID: 15345593
[TBL] [Abstract][Full Text] [Related]
10. FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).
Bagrintseva K; Geisenhof S; Kern R; Eichenlaub S; Reindl C; Ellwart JW; Hiddemann W; Spiekermann K
Blood; 2005 May; 105(9):3679-85. PubMed ID: 15626738
[TBL] [Abstract][Full Text] [Related]
11. Tyk2 is dispensable for induction of myeloproliferative disease by mutant FLT3.
Nakajima H; Shibata F; Kumagai H; Shimoda K; Kitamura T
Int J Hematol; 2006 Jul; 84(1):54-9. PubMed ID: 16867903
[TBL] [Abstract][Full Text] [Related]
12. Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.
Rocnik JL; Okabe R; Yu JC; Lee BH; Giese N; Schenkein DP; Gilliland DG
Blood; 2006 Aug; 108(4):1339-45. PubMed ID: 16627759
[TBL] [Abstract][Full Text] [Related]
13. SRC is a signaling mediator in FLT3-ITD- but not in FLT3-TKD-positive AML.
Leischner H; Albers C; Grundler R; Razumovskaya E; Spiekermann K; Bohlander S; Rönnstrand L; Götze K; Peschel C; Duyster J
Blood; 2012 Apr; 119(17):4026-33. PubMed ID: 22411868
[TBL] [Abstract][Full Text] [Related]
14. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
[TBL] [Abstract][Full Text] [Related]
15. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.
Mizuki M; Fenski R; Halfter H; Matsumura I; Schmidt R; Müller C; Grüning W; Kratz-Albers K; Serve S; Steur C; Büchner T; Kienast J; Kanakura Y; Berdel WE; Serve H
Blood; 2000 Dec; 96(12):3907-14. PubMed ID: 11090077
[TBL] [Abstract][Full Text] [Related]
16. Lineage-specific STAT5 target gene activation in hematopoietic progenitor cells predicts the FLT3(+)-mediated leukemic phenotype.
Müller TA; Grundler R; Istvanffy R; Rudelius M; Hennighausen L; Illert AL; Duyster J
Leukemia; 2016 Aug; 30(8):1725-33. PubMed ID: 27046463
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.
Tse KF; Allebach J; Levis M; Smith BD; Bohmer FD; Small D
Leukemia; 2002 Oct; 16(10):2027-36. PubMed ID: 12357354
[TBL] [Abstract][Full Text] [Related]
18. Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia.
Janke H; Pastore F; Schumacher D; Herold T; Hopfner KP; Schneider S; Berdel WE; Büchner T; Woermann BJ; Subklewe M; Bohlander SK; Hiddemann W; Spiekermann K; Polzer H
PLoS One; 2014; 9(3):e89560. PubMed ID: 24608088
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.
Grundler R; Thiede C; Miething C; Steudel C; Peschel C; Duyster J
Blood; 2003 Jul; 102(2):646-51. PubMed ID: 12663439
[TBL] [Abstract][Full Text] [Related]
20. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
O'Farrell AM; Abrams TJ; Yuen HA; Ngai TJ; Louie SG; Yee KW; Wong LM; Hong W; Lee LB; Town A; Smolich BD; Manning WC; Murray LJ; Heinrich MC; Cherrington JM
Blood; 2003 May; 101(9):3597-605. PubMed ID: 12531805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]